Current Updates in Gene Therapy for Multiple Sclerosis
Hossam Tharwat Ali
Mennatullah Mohamed Eltaras
Al-Quds University - Deanship of Scientific Research
Background: Multiple sclerosis (MS) is the most common demyelinating disease affecting predominantly young adults. The underlying pathogenesis isn’t fully understood although autoimmune attacks against proteins in the CNS is the most accepted theory. Oligodendrocytes seem to be the most involved resulting in demyelinated axons. Currently, the management of MS focuses on relieving symptoms during acute attacks and preventing disease progression using disease-odifying agents such as interferon-beta, dimethyl fumarate, natalizumab, and fingolimod. Studies have proven long-term improvement on these drugs. However, possible side effects and curatively inducing or improving the repair process are major challenges.